Financials in USD. Standardized financial statements.
A compact view of how Cardiff Oncology, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $593,000 | $683,000 | $488,000 | $386,000 | $359,000 | $366,000 | $244,632 | $378,000 | $505,000 | $381,000 |
| Revenue Growth? | -13.2% | +40.0% | +26.4% | +7.5% | -1.9% | +49.6% | -35.3% | -25.1% | +32.5% | 0.0% |
| Cost of Revenue? | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $597,000 | $1.81M | $1.73M |
| Gross Profit? | $593,000 | $683,000 | $488,000 | $386,000 | $359,000 | $366,000 | $244,632 | -$219,000 | -$1.31M | -$1.35M |
| Gross Margin? | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% | +100.0% | -57.9% | -258.6% | -354.1% |
| Operating Expenses? | $49.55M | $49.33M | $45.90M | $40.29M | $29.21M | $19.45M | $16.92M | $16.17M | $22.11M | $38.01M |
| Operating Income? | -$48.96M | -$48.65M | -$45.41M | -$39.90M | -$28.86M | -$19.09M | -$16.68M | -$17.05M | -$25.60M | -$40.15M |
| EBITDA? | -$48.06M | -$48.25M | -$45.01M | -$39.67M | -$28.40M | -$18.84M | -$15.92M | -$15.70M | -$22.82M | -$36.76M |
| Income Before Tax | -$45.85M | -$45.43M | -$41.44M | -$38.70M | -$28.29M | -$19.31M | -$16.41M | -$16.46M | -$24.91M | -$39.20M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $617,643 | $716,000 | -$296,000 |
| Net Income? | -$45.85M | -$45.43M | -$41.44M | -$38.70M | -$28.29M | -$19.31M | -$16.41M | -$16.46M | -$24.91M | -$39.20M |
| EPS? | $-0.69 | $-0.95 | $-0.93 | $-0.89 | $-0.73 | $-1.08 | $-2.70 | $-7.06 | $-51.71 | $-93.54 |
| Diluted EPS? | $-0.69 | $-0.95 | $-0.93 | $-0.89 | $-0.73 | $-1.08 | $-2.70 | $-7.06 | $-51.71 | $-93.22 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality